Europe sidelines Alzheimer's drug: lessons must be learnt - Nature
The EMA's refusal to approve lecanemab, a drug for early Alzheimer's, contrasts with its approval in multiple countries. Critics argue the EMA overestimated risks and underestimated benefits, despite manageable side effects. The EMA's exclusion of researchers with industry ties, seen as a conflict of interest, may hinder objective assessments and slow drug approvals.
Reference News
Europe sidelines Alzheimer's drug: lessons must be learnt - Nature
The EMA's refusal to approve lecanemab, a drug for early Alzheimer's, contrasts with its approval in multiple countries. Critics argue the EMA overestimated risks and underestimated benefits, despite manageable side effects. The EMA's exclusion of researchers with industry ties, seen as a conflict of interest, may hinder objective assessments and slow drug approvals.